{"commentary":{"count":131,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":54,"x_thread":46,"youtube":30,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04322539\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"FRESCO-2","nct_id":"NCT04322539","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fresco-2-nct04322539. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"FRESCO-2","arms":[{"description":"Participants will be orally administered Fruquintinib 5 mg in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break (with each cycle length of 28 days).","label":"Fruquintinib Plus Best Supportive Care (BSC) Group","type":"EXPERIMENTAL"},{"description":"Participants will be orally administered Placebo 5 mg in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break (with each cycle length of 28 days).","label":"Placebo Plus BSC Group","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-04-24","type":"ACTUAL"},"conditions":["Metastatic Colorectal Cancer","Metastatic Colon Cancer"],"enrollment":{"count":691,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Fruquintinib","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2025-04-04","lead_sponsor":"Hutchison Medipharma Limited","official_title":"A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-07-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"From date of randomization to death from any cause (up to 22 months)"}],"references":[{"citation":"Kotani D, Yoshino T, Masuishi T, Sunakawa Y, Takashima A, Yamazaki K, Kawakami H, Nishina T, Komatsu Y, Esaki T, Eng C, Ukrainskyj S, Pallai R, Nanda S, Yang Z, Schelman W, Kania M, Satoh T. Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. Int J Clin Oncol. 2025 Oct;30(10):2043-2052. doi: 10.1007/s10147-025-02852-9. Epub 2025 Sep 1.","pmid":"40888992","type":"DERIVED"},{"citation":"Zhou X, Toms A, Morton D, Wang X, Taylor A, Dasari A, Gupta N, Chien C. Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer. J Clin Pharmacol. 2025 Nov;65(11):1411-1419. doi: 10.1002/jcph.70051. Epub 2025 Jun 8.","pmid":"40485075","type":"DERIVED"},{"citation":"Eng C, Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Yang Z, Guevara F, Schelman W, Pallai R, Tabernero J. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. Oncologist. 2025 Mar 10;30(3):oyae360. doi: 10.1093/oncolo/oyae360.","pmid":"40163688","type":"DERIVED"},{"citation":"Sobrero A, Dasari A, Aquino J, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Yao J, Garcia-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Price T, Yu Z, Geiger A, Chen L, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C. Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study. Eur J Cancer. 2025 Mar 11;218:115268. doi: 10.1016/j.ejca.2025.115268. Epub 2025 Jan 29.","pmid":"39952149","type":"DERIVED"},{"citation":"Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csoszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15.","pmid":"37331369","type":"DERIVED"},{"citation":"Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol. 2021 Aug;17(24):3151-3162. doi: 10.2217/fon-2021-0202. Epub 2021 May 17.","pmid":"33993740","type":"DERIVED"}],"start_date":{"date":"2020-08-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT04322539"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fresco-2-nct04322539"}